CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Revenue:
Total revenue	$ 181,398	$ 100,049	$ 302,314	$ 180,727
Costs and operating expenses:
Selling and marketing expense	42,260	38,710	82,089	78,319
General and administrative expense (see note 10)	64,367	41,068	116,486	85,422
Research and development expense	25,047	24,787	48,114	59,164
Total costs and operating expenses	199,387	167,060	378,254	339,961
Loss from operations	(17,989)	(67,011)	(75,940)	(159,234)
Other income (expense), net:
Interest income	1,618	2,640	2,121	4,408
Interest expense	(19,208)	(13,674)	(31,990)	(22,964)
Changes in fair value of financial instruments	(17,870)	12,000	(50,203)	936
Other expense, net	(18,341)	(141)	(18,358)	(360)
Total other income (expense), net	(53,801)	825	(98,430)	(17,980)
Loss before income taxes and provision for income taxes	(71,790)	(66,186)	(174,370)	(177,214)
Provision for income taxes	0	0	0	0
Net loss	(71,790)	(66,186)	(174,370)	(177,214)
Net income (loss)	(71,790)	(66,186)	(174,370)	(177,214)
Other comprehensive income, net of tax:
Unrealized gain on available-for-sale securities	0	0	0	7
Foreign currency translation adjustments	424	92	459	100
Comprehensive loss	(71,366)	(66,094)	(173,911)	(177,107)
Deemed dividend from Series D redeemable convertible preferred stock (see note 6)	(384,436)	0	(384,436)	0
Adjustments of redeemable convertible preferred stock to redemption value	(60,971)	(23,594)	(85,433)	(46,707)
Net loss attributable to common shareholders basic	(517,197)	(89,780)	(644,239)	(223,921)
Net loss attributable to common shareholders diluted	$ (517,197)	$ (89,780)	$ (644,239)	$ (223,921)
Net loss per share attributable to common shareholders - basic (in dollars per share)	$ (7.97)	$ (2.54)	$ (12.80)	$ (6.34)
Net loss per share attributable to common shareholders - diluted (in dollars per share)	$ (7.97)	$ (2.54)	$ (12.80)	$ (6.34)
Weighted-average shares used in computing net loss per share attributable to common shareholders - basic (in shares)	64,918,988	35,371,424	50,348,947	35,342,180
Weighted-average shares used in computing net loss per share attributable to common shareholders - diluted (in shares)	64,918,988	35,371,424	50,348,947	35,342,180
Molecular Profiling Services
Revenue:
Total revenue	$ 162,924	$ 87,656	$ 277,006	$ 160,890
Costs and operating expenses:
Cost of services	65,321	59,431	126,215	112,324
Pharma Research And Development Services
Revenue:
Total revenue	18,474	12,393	25,308	19,837
Costs and operating expenses:
Cost of services	$ 2,392	$ 3,064	$ 5,350	$ 4,732